ADMA logo

ADMA Biologics (ADMA) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

17 October 2013

Indexes:

Not included

Description:

ADMA Biologics is a biotechnology company that develops and produces specialty plasma-derived therapies. They focus on treating immune deficiencies and infectious diseases, using human plasma to create products that help patients with serious health conditions. Their goal is to improve patient outcomes through innovative treatments.

Key Details

Price

$21.65

Annual Revenue

$258.21 M(+67.59% YoY)

Annual EPS

-$0.13(+60.61% YoY)

Annual ROE

-19.67%

Beta

1.74

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 07, 2024

Recent annual earnings:

Feb 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

08 Nov '24 Raymond James
Strong Buy
08 Nov '24 HC Wainwright & Co.
Buy
14 Oct '24 HC Wainwright & Co.
Buy
20 Sept '24 Cantor Fitzgerald
Overweight
12 Aug '24 HC Wainwright & Co.
Buy
09 Aug '24 Cantor Fitzgerald
Overweight
09 July '24 Cantor Fitzgerald
Overweight
20 June '24 Mizuho
Buy
10 May '24 Raymond James
Strong Buy
10 May '24 Mizuho
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

The Schall Law Firm Invites Stockholder Contributions To An Inquiry Into ADMA Biologics Inc's Securities Law Violations
The Schall Law Firm Invites Stockholder Contributions To An Inquiry Into ADMA Biologics Inc's Securities Law Violations
The Schall Law Firm Invites Stockholder Contributions To An Inquiry Into ADMA Biologics Inc's Securities Law Violations
ADMA
accesswire.com27 November 2024

LOS ANGELES, CA / ACCESSWIRE / November 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
ADMA
accesswire.com27 November 2024

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
ADMA
accesswire.com26 November 2024

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

ADMA Biologics, Inc. Is Being Investigated For Engaging In Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law Firm
ADMA Biologics, Inc. Is Being Investigated For Engaging In Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law Firm
ADMA Biologics, Inc. Is Being Investigated For Engaging In Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law Firm
ADMA
accesswire.com24 November 2024

LOS ANGELES, CA / ACCESSWIRE / November 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

The Schall Law Firm Wants Shareholders To Join An Inquiry Into ADMA Biologics Inc's Securities Law Violations
The Schall Law Firm Wants Shareholders To Join An Inquiry Into ADMA Biologics Inc's Securities Law Violations
The Schall Law Firm Wants Shareholders To Join An Inquiry Into ADMA Biologics Inc's Securities Law Violations
ADMA
accesswire.com23 November 2024

LOS ANGELES, CA / ACCESSWIRE / November 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Contact The Schall Law Firm
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Contact The Schall Law Firm
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Contact The Schall Law Firm
ADMA
accesswire.com22 November 2024

LOS ANGELES, CA / ACCESSWIRE / November 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMA
ADMA
accesswire.com20 November 2024

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ:ADMA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Help The Schall Law Firm
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Help The Schall Law Firm
ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Help The Schall Law Firm
ADMA
accesswire.com20 November 2024

LOS ANGELES, CA / ACCESSWIRE / November 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations
ADMA
accesswire.com19 November 2024

LOS ANGELES, CA / ACCESSWIRE / November 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ:ADMA) for violations of the securities laws. According to the Complaint, the Company made false and misleading statements to the market.

Wall Street Analysts See a 31.3% Upside in Adma Biologics (ADMA): Can the Stock Really Move This High?
Wall Street Analysts See a 31.3% Upside in Adma Biologics (ADMA): Can the Stock Really Move This High?
Wall Street Analysts See a 31.3% Upside in Adma Biologics (ADMA): Can the Stock Really Move This High?
ADMA
zacks.com18 November 2024

The average of price targets set by Wall Street analysts indicates a potential upside of 31.3% in Adma Biologics (ADMA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

FAQ

  • What is the primary business of ADMA Biologics?
  • What is the ticker symbol for ADMA Biologics?
  • Does ADMA Biologics pay dividends?
  • What sector is ADMA Biologics in?
  • What industry is ADMA Biologics in?
  • What country is ADMA Biologics based in?
  • When did ADMA Biologics go public?
  • Is ADMA Biologics in the S&P 500?
  • Is ADMA Biologics in the NASDAQ 100?
  • Is ADMA Biologics in the Dow Jones?
  • When was ADMA Biologics's last earnings report?
  • When does ADMA Biologics report earnings?
  • Should I buy ADMA Biologics stock now?

What is the primary business of ADMA Biologics?

ADMA Biologics is a biotechnology company that develops and produces specialty plasma-derived therapies. They focus on treating immune deficiencies and infectious diseases, using human plasma to create products that help patients with serious health conditions. Their goal is to improve patient outcomes through innovative treatments.

What is the ticker symbol for ADMA Biologics?

The ticker symbol for ADMA Biologics is NASDAQ:ADMA

Does ADMA Biologics pay dividends?

No, ADMA Biologics does not pay dividends

What sector is ADMA Biologics in?

ADMA Biologics is in the Healthcare sector

What industry is ADMA Biologics in?

ADMA Biologics is in the Biotechnology industry

What country is ADMA Biologics based in?

ADMA Biologics is headquartered in United States

When did ADMA Biologics go public?

ADMA Biologics's initial public offering (IPO) was on 17 October 2013

Is ADMA Biologics in the S&P 500?

No, ADMA Biologics is not included in the S&P 500 index

Is ADMA Biologics in the NASDAQ 100?

No, ADMA Biologics is not included in the NASDAQ 100 index

Is ADMA Biologics in the Dow Jones?

No, ADMA Biologics is not included in the Dow Jones index

When was ADMA Biologics's last earnings report?

ADMA Biologics's most recent earnings report was on 7 November 2024

When does ADMA Biologics report earnings?

The next expected earnings date for ADMA Biologics is 28 February 2025

Should I buy ADMA Biologics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions